PRPH: ProPhase Labs, Inc.
About
ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. It operates through the Diagnostic Services and Consumer Products segment. The Diagnostic Services segment includes COVID-19 and other diagnostic testing services. The Consumer Products segment consists of the manufacturing, retail customers, and personal genomics products and services. The company was founded by Guy J. Quigley and Charles A. Phillips in July 1989 and is headquartered in Garden City, NY.
Current Value
$0.781 Year Return
Current Value
$0.781 Year Return
Key Details
Market Cap
$18.55M
P/E Ratio
-0.52
1Y Stock Return
-82.54%
1Y Revenue Growth
-79.66%
Dividend Yield
0.00%
Price to Book
0.4
Strategies that include PRPH
Stock's related to PRPH
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| KELYA | 34.48% | $495.69M | -33.84% | 2.69% |
| EVH | 33.49% | $1.35B | -60.78% | 0.00% |
| RXST | 30.90% | $1.82B | +57.90% | 0.00% |
| PSEC | 30.17% | - | - | 15.48% |
| PINS | 27.63% | $19.81B | -7.71% | 0.00% |
| ITCI | 25.03% | $9.06B | +44.20% | 0.00% |
| GRMN | 23.41% | $40.15B | +73.72% | 1.41% |
| PTMN | 23.26% | - | - | 16.24% |
| ALTO | 21.99% | $108.84M | -40.08% | 0.00% |
| RCKY | 21.15% | $155.86M | -22.44% | 2.93% |
| WHF | 21.08% | - | - | 14.69% |
| APPS | 20.87% | $152.48M | -70.95% | 0.00% |
| ATNM | 20.56% | $45.86M | -66.74% | 0.00% |
| AVDL | 20.02% | $1.12B | +2.01% | 0.00% |
| ASC | 19.40% | $497.50M | -11.99% | 9.03% |
| NCMI | 19.02% | $646.37M | +63.31% | 0.00% |
| ARCT | 18.87% | $462.38M | -27.45% | 0.00% |
| ARQ | 18.71% | $318.18M | +179.34% | 0.00% |
| DIS | 18.70% | $207.75B | +20.67% | 0.39% |
| SGC | 18.64% | $268.98M | +38.79% | 4.24% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DORM | -<0.01% | $4.18B | +88.42% | 0.00% |
| BALL | -0.01% | $18.15B | +13.51% | 1.31% |
| PDCO | -0.01% | $1.79B | -37.23% | 5.13% |
| MGTX | 0.01% | $462.67M | +9.43% | 0.00% |
| CRGY | -0.01% | $2.46B | +33.39% | 3.16% |
| AEG | -0.02% | $10.11B | +17.23% | 5.63% |
| ARW | -0.02% | $6.15B | -2.56% | 0.00% |
| ABT | -0.03% | $203.38B | +14.18% | 1.87% |
| ARHS | 0.03% | $1.35B | +11.23% | 0.00% |
| AA | 0.03% | $12.00B | +76.08% | 0.86% |
| JACK | -0.03% | $914.22M | -31.84% | 3.69% |
| MOS | -0.03% | $8.27B | -27.66% | 3.20% |
| LVO | -0.03% | $79.50M | -18.53% | 0.00% |
| FBNC | -0.03% | $1.93B | +49.46% | 1.87% |
| CUZ | 0.04% | $4.98B | +58.79% | 4.04% |
| OMI | 0.05% | $943.04M | -36.76% | 0.00% |
| TPL | -0.05% | $34.82B | +180.72% | 0.57% |
| LOCO | -0.05% | $361.96M | +37.39% | 0.00% |
| HLIO | -0.05% | $1.74B | +32.30% | 0.68% |
| ZION | -0.06% | $8.74B | +71.87% | 2.81% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AXON | -35.84% | $48.14B | +178.25% | 0.00% |
| FTRE | -31.45% | $1.75B | -40.64% | 0.00% |
| APP | -31.05% | $106.80B | +711.01% | 0.00% |
| TASK | -30.75% | $1.32B | +20.62% | 0.00% |
| DOCS | -29.21% | $8.96B | +95.76% | 0.00% |
| FLYW | -28.05% | $2.85B | -1.08% | 0.00% |
| UEIC | -24.97% | $152.04M | +56.02% | 0.00% |
| UPST | -23.78% | $6.52B | +204.22% | 0.00% |
| UI | -23.36% | $20.91B | +200.47% | 0.69% |
| FARO | -23.19% | $497.53M | +43.95% | 0.00% |
| MSI | -21.00% | $82.70B | +54.87% | 0.79% |
| AAOI | -20.91% | $1.60B | +168.74% | 0.00% |
| BROS | -20.04% | $5.93B | +80.24% | 0.00% |
| SONY | -19.39% | $115.03B | +8.86% | 1.50% |
| BILL | -19.19% | $9.31B | +41.43% | 0.00% |
| ALRM | -18.81% | $3.00B | +6.46% | 0.00% |
| G | -18.69% | $8.08B | +36.94% | 1.28% |
| PLNT | -18.30% | $8.42B | +51.73% | 0.00% |
| ADTN | -18.22% | $646.67M | +51.39% | 0.00% |
| PODD | -17.87% | $18.38B | +40.63% | 0.00% |
ETF's related to PRPH
News
Yahoo
HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that Frank D. Heuszel, Chairman and Chief Executive Officer of Impact BioMedical Inc., issued the following letter to Impact BioMedical shareholders regarding recent achievements, executional efficiencies and the positive outlook for the Company’s future. Dear Impact Biomedic
Yahoo
ProPhase Labs Inc (PRPH) outlines aggressive product launches and cost-cutting measures while addressing significant accounts receivable issues.
Yahoo
New York, NY, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an Update Note on ProPhase Labs Inc. (NASDAQ: PRPH). The update note includes information on ProPhase’s business model, services offered, industry outlook, financial results, management commentary, valuation, and risks. The update note is available below. ProPhase Labs November 2024 Update Note Highlights from the note include: Launch
SeekingAlpha
ProPhase Labs, Inc. (NASDAQ:PRPH) Q3 2024 Results Conference Call November 13, 2024 11:00 AM ETCompany ParticipantsNoella Alexander-Young - Renmark...
Yahoo
ProPhase Labs (PRPH) delivered earnings and revenue surprises of -12.90% and 11.56%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
Highlights Q4 2024 and Q1 2025 with multiple potential liquidity events, growth in multiple subsidiaries as well as potentially significant reduction in overhead and expenses Company to hold a virtual conference call Wednesday, November 13, 2024, at 11:00 AM ET GARDEN CITY, NY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its financial and operational results for th
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.